Ildong Holdings (A000230) Stock Overview
Develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 1/6 |
A000230 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Ildong Holdings Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩9,230.00 |
| 52 Week High | ₩12,220.00 |
| 52 Week Low | ₩5,470.00 |
| Beta | 0.71 |
| 1 Month Change | 30.00% |
| 3 Month Change | 51.56% |
| 1 Year Change | 21.29% |
| 3 Year Change | -70.79% |
| 5 Year Change | 6.95% |
| Change since IPO | 388.20% |
Recent News & Updates
Ildong Holdings Co., Ltd.'s (KRX:000230) Shares Bounce 38% But Its Business Still Trails The Industry
Jul 07
Shareholders Will Be Pleased With The Quality of Ildong Holdings' (KRX:000230) Earnings
Mar 25Recent updates
Ildong Holdings Co., Ltd.'s (KRX:000230) Shares Bounce 38% But Its Business Still Trails The Industry
Jul 07Shareholders Will Be Pleased With The Quality of Ildong Holdings' (KRX:000230) Earnings
Mar 25Revenues Working Against Ildong Holdings Co., Ltd.'s (KRX:000230) Share Price
Dec 18Is Ildong Holdings (KRX:000230) Using Debt Sensibly?
Nov 12Ildong Holdings Co., Ltd. (KRX:000230) Shares Fly 39% But Investors Aren't Buying For Growth
Aug 20Is Ildong Holdings Co., Ltd. (KRX:000230) A Good Dividend Stock?
Apr 28Can You Imagine How Ildong Holdings' (KRX:000230) Shareholders Feel About The 60% Share Price Increase?
Mar 04Ildong Holdings (KRX:000230) Has Debt But No Earnings; Should You Worry?
Feb 06
Tread With Caution Around Ildong Holdings Co., Ltd.'s (KRX:000230) 0.7% Dividend Yield
Jan 11How Much Of Ildong Holdings Co., Ltd. (KRX:000230) Do Insiders Own?
Dec 16How Much Have Ildong Holdings (KRX:000230) Shareholders Earned On Their Investment Over The Last Five Years?
Nov 20Shareholder Returns
| A000230 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 26.4% | 2.0% | 1.7% |
| 1Y | 21.3% | -2.2% | 5.5% |
Return vs Industry: A000230 exceeded the KR Pharmaceuticals industry which returned -2.6% over the past year.
Return vs Market: A000230 exceeded the KR Market which returned 4.9% over the past year.
Price Volatility
| A000230 volatility | |
|---|---|
| A000230 Average Weekly Movement | 11.2% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.0% |
Stable Share Price: A000230's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A000230's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 72 | Dae-Chang Park | www.ildongholdings.co.kr |
Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer’s disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It is also involved in the research and manufacture of health foods and ingredients; and provides hyaluronic acid for use in drugs, medical devices, and cosmetics.
Ildong Holdings Co., Ltd. Fundamentals Summary
| A000230 fundamental statistics | |
|---|---|
| Market cap | ₩104.23b |
| Earnings (TTM) | ₩64.40b |
| Revenue (TTM) | ₩645.47b |
Is A000230 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A000230 income statement (TTM) | |
|---|---|
| Revenue | ₩645.47b |
| Cost of Revenue | ₩415.30b |
| Gross Profit | ₩230.18b |
| Other Expenses | ₩165.78b |
| Earnings | ₩64.40b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.70k |
| Gross Margin | 35.66% |
| Net Profit Margin | 9.98% |
| Debt/Equity Ratio | 119.6% |
How did A000230 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/09 05:26 |
| End of Day Share Price | 2025/07/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ildong Holdings Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kidal Bae | Shinhan Investment Corp. |